CN114144493A - 治疗和减轻酒精诱导的皮肤潮红的组合物和方法 - Google Patents

治疗和减轻酒精诱导的皮肤潮红的组合物和方法 Download PDF

Info

Publication number
CN114144493A
CN114144493A CN202080052527.2A CN202080052527A CN114144493A CN 114144493 A CN114144493 A CN 114144493A CN 202080052527 A CN202080052527 A CN 202080052527A CN 114144493 A CN114144493 A CN 114144493A
Authority
CN
China
Prior art keywords
subject
pharmaceutical composition
aldh2
alcohol
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080052527.2A
Other languages
English (en)
Chinese (zh)
Inventor
爱德华·K·Y·荣格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Browster LLC
Original Assignee
Ekyj Ii Consulting Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ekyj Ii Consulting Co ltd filed Critical Ekyj Ii Consulting Co ltd
Priority to CN202411836532.9A priority Critical patent/CN119909065A/zh
Publication of CN114144493A publication Critical patent/CN114144493A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202080052527.2A 2019-05-23 2020-05-22 治疗和减轻酒精诱导的皮肤潮红的组合物和方法 Pending CN114144493A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411836532.9A CN119909065A (zh) 2019-05-23 2020-05-22 治疗和减轻酒精诱导的皮肤潮红的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852000P 2019-05-23 2019-05-23
US62/852,000 2019-05-23
PCT/US2020/034273 WO2020237172A1 (en) 2019-05-23 2020-05-22 Compositions and methods for the treatment and mitigation of alcohol-induced skin flushing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411836532.9A Division CN119909065A (zh) 2019-05-23 2020-05-22 治疗和减轻酒精诱导的皮肤潮红的组合物和方法

Publications (1)

Publication Number Publication Date
CN114144493A true CN114144493A (zh) 2022-03-04

Family

ID=73458156

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080052527.2A Pending CN114144493A (zh) 2019-05-23 2020-05-22 治疗和减轻酒精诱导的皮肤潮红的组合物和方法
CN202411836532.9A Pending CN119909065A (zh) 2019-05-23 2020-05-22 治疗和减轻酒精诱导的皮肤潮红的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411836532.9A Pending CN119909065A (zh) 2019-05-23 2020-05-22 治疗和减轻酒精诱导的皮肤潮红的组合物和方法

Country Status (7)

Country Link
US (1) US20220226286A1 (https=)
EP (1) EP3973030A4 (https=)
JP (2) JP2022536408A (https=)
KR (1) KR20220012903A (https=)
CN (2) CN114144493A (https=)
TW (1) TW202110437A (https=)
WO (1) WO2020237172A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102879756B1 (ko) 2022-11-11 2025-11-12 대한민국 이상지질혈증 예측 또는 진단용 snp 마커 및 이의 용도
KR102893400B1 (ko) 2022-11-21 2025-12-02 대한민국 당뇨병 예측 또는 진단용 hectd4 snp 마커 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565876B1 (en) * 1999-04-22 2003-05-20 Sigma-Tau Healthscience S.P.A. Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug
US20130150419A1 (en) * 2004-03-03 2013-06-13 Raptor Therapeutiacs Inc. 4-methylpyrazole formulations for inhibiting ethanol intolerance
US20170252312A1 (en) * 2014-09-15 2017-09-07 Biohit Oyj Preparations for treatment and prevention of alcohol flushing and alcohol-induced hypersensitivity reactions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6468319A (en) * 1987-09-09 1989-03-14 Nonogawa Shoji Yk Anti-inflammatory
JPH01287035A (ja) * 1988-05-13 1989-11-17 Sanwa Kagaku Kenkyusho Co Ltd 薬物並びにアルコール性中毒の予防剤とその治療剤
TW271400B (https=) * 1992-07-30 1996-03-01 Pfizer
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
DK1909600T3 (da) * 2005-07-29 2012-07-30 Tima Foundation Sammensætning til moderering af alkoholmetabolisme og til at reducere risikoen for alkoholforårsagede sygdomme
US20110105602A2 (en) * 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
JP2011051942A (ja) * 2009-09-03 2011-03-17 Glovia:Kk 認知症治療薬
CN102549171A (zh) * 2009-10-07 2012-07-04 学校法人武库川学院 基因型的判断方法
ES2646201T3 (es) * 2009-12-07 2017-12-12 Horizon Orphan Llc Formulaciones de 4-metilpirazol
WO2012027326A2 (en) * 2010-08-24 2012-03-01 The Regents Of The University Of California Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
EP3323412A1 (en) * 2016-11-17 2018-05-23 Amalicon Holding AG Formulation comprising 4-methylpyrazole

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565876B1 (en) * 1999-04-22 2003-05-20 Sigma-Tau Healthscience S.P.A. Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug
US20130150419A1 (en) * 2004-03-03 2013-06-13 Raptor Therapeutiacs Inc. 4-methylpyrazole formulations for inhibiting ethanol intolerance
US20170252312A1 (en) * 2014-09-15 2017-09-07 Biohit Oyj Preparations for treatment and prevention of alcohol flushing and alcohol-induced hypersensitivity reactions

Also Published As

Publication number Publication date
CN119909065A (zh) 2025-05-02
WO2020237172A1 (en) 2020-11-26
EP3973030A4 (en) 2023-05-31
TW202110437A (zh) 2021-03-16
US20220226286A1 (en) 2022-07-21
KR20220012903A (ko) 2022-02-04
JP2022536408A (ja) 2022-08-15
JP2025093991A (ja) 2025-06-24
EP3973030A1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
ES2347968T3 (es) Preparacion solida que se disgrega rapidamente.
JP4454791B2 (ja) 医薬製剤
US20190231766A1 (en) Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US20180221359A1 (en) Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
JP2025093991A (ja) アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法
CN102036656A (zh) 含有蜡的缓释制剂
CA2533588A1 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
CN102802418A (zh) 用于治疗肌萎缩性侧索硬化的组合物和方法
BR112019023101A2 (pt) composições farmacêuticas e métodos de tratamento para doenças cardiovasculares
JP7136763B2 (ja) フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
US20140112983A1 (en) Nitrite compositions and uses thereof
EA016683B1 (ru) Фармацевтический препарат для перорального введения с контролируемым высвобождением активного ингредиента в тонком кишечнике и способ его получения
NO342977B1 (no) Racecadotriltablett, fremgangsmåte for fremstilling av slike og slike tabletter for behandling av diaré
EP4463157B1 (en) Treatment of gm2 gangliosidosis
CN114650825A (zh) 治疗高苯丙氨酸血症的方法
US20220323409A1 (en) Modified release formulations and uses thereof
HU229569B1 (hu) Szelektív szerotoninújrafelvétel-gátlók szabályozott kibocsátású többrészecskés kiszerelései
US20240156752A1 (en) Endoxifen for treatment of ovarian cancer
WO2016154313A1 (en) High drug loading liquid oral pharmaceutical compositions
JP6012622B2 (ja) ホスホマイシン医薬組成物
CN100431526C (zh) 一种酸敏感型药物的快速崩解片剂
CN116723870A (zh) 球形细胞脑白质营养不良症或克拉伯病的改良治疗
CN110623955A (zh) Wnk激酶抑制剂在预防和/或治疗高原病中的用途
KR20240070564A (ko) 알츠하이머병 예방 또는 치료용 약학적 조성물
HK40111138A (zh) 含有非索非那定的组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230911

Address after: Nevada

Applicant after: Browster LLC

Address before: Nevada

Applicant before: Ekyj II Consulting Co.,Ltd.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220304

WD01 Invention patent application deemed withdrawn after publication